Trade Names:Lopid- Tablets 600 mgApo-Gemfibrozil (Canada)Gen-Gemfibrozil (Canada)PMS-Gemfibrozil (Canada)
Decreases blood levels of triglycerides and VLDL by decreasing their production. Also decreases cholesterol and increases HDL.
Bioavailability is 100%. T max is 1 to 2 h.Food
Max rate of absorption and a 50% to 60% increase in C max when administered 30 min before meals vs with meals or fasting.
Protein binding is high.
Mainly undergoes oxidation to form a hydroxymethyl and a carboxyl metabolite.
Plasma t ½ is 1.5 h, biological t ½ is longer because of enterohepatic circulation and reabsorption in the GI tract. Approximately 70% excreted in urine (about 2% as unchanged); 6% excreted in feces.
Treatment of hypertriglyceridemia in adult patients with type IV or V hyperlipidemia that presents risk of pancreatitis and does not respond to diet; reduction of coronary heart disease risk in type IIb patients who have low HDL levels (in addition to elevated LDL and triglycerides) and have not responded to other measures.
Hepatic or severe renal function impairment, including primary biliary cirrhosis; preexisting gallbladder disease.
PO 600 mg twice daily 30 min before morning and evening meals.
Store at room temperature in a tightly closed container.
Increases risk of rhabdomyolysis.Oral anticoagulants (eg, warfarin)
Anticoagulant effect may be increased.
None well documented.
Fatigue; vertigo; headache.
Dyspepsia; abdominal pain; diarrhea; nausea; vomiting; constipation; acute appendicitis.
Anemia; leukopenia; bone marrow hypoplasia; eosinophilia.
Elevated LFT results; cholestatic jaundice.
Muscle pain or weakness; myositis; rhabdomyolysis; taste perversions.
Category B .
Safety and efficacy not established.
Drug may increase cholesterol excretion into the bile, leading to cholelithiasis.
Copyright © 2009 Wolters Kluwer Health.